

**Session:** 277. Vaccines: Bacterial  
 Saturday, October 5, 2019: 12:15 PM

**Background:** Many jurisdictions report a significant reduction in invasive pneumococcal disease (IPD) in adults following implementation of the pneumococcal conjugate vaccines, 7-valent (PCV7) and 13-valent (PCV13) in childhood immunization programs. This study evaluates the indirect effect of conjugate vaccines on IPD in British Columbia, Canada over a 14 year period (2002–2015).

**Methods:** Using provincial IPD laboratory surveillance data, we calculated the annual incidence following implementation of PCV7 (September 2004), and PCV13 (September 2010) in adults 18 years of age and older. We also compared incidence rate ratios (IRR) against pre-PCV13 (2004–2010) and pre-PCV7 (2002–2003) baselines for overall and age-specific IPD rates using Poisson regression.

**Results:** A total of 3793 cases were reported over the 14 year period. The overall annual incidence increased from 4.32 cases per 100,000 population in 2002 to 8.61 cases per 100,000 population in 2015. Overall, IPD has increased by 80% (IRR: 1.80; 95% CI: 1.59–2.04) compared with baseline, especially in adults  $\geq$  85 years of age (PCV13 vs baseline: IRR: 1.90; 95% CI: 1.25–03.05). This increase was the highest after introduction of PCV7 (IRR: 1.87; 95% CI: 1.65–2.11); the incremental change after introduction of PCV13 was non-significant (IRR 0.96; 95% CI: 0.90–1.03). While PCV7 type IPD plummeted by 76% (IRR 0.24; 95% CI: 0.18–0.31) since introduction of PCV7 compared with baseline, a modest decline in PCV13 type IPD of 20% was seen (IRR 0.80; 95% CI: 0.71–0.89) since introduction of PCV13.

**Conclusion:** Although PCV7-type IPD has decreased substantially, only a modest reduction in IPD from the additional 6 serotypes in the PCV13 vaccine was observed.

**Disclosures.** All authors: No reported disclosures.

**2707. Non 13-Valent Pneumococcal Conjugate Vaccine Serotypes Predominate as Causes of Pneumococcal Otitis Media in Children**

Kristina G. Hulten, PhD<sup>1</sup>; William J. Barson, MD<sup>2</sup>; P. Ling. Lin, MD<sup>3</sup>; John S. Bradley, MD<sup>4</sup>; Timothy R. Peters, MD<sup>5</sup>; Tina Q. Tan, MD<sup>6</sup>; Jose R. Romero, MD<sup>7</sup>; Pia S. Pannaraj, MD<sup>8</sup>; Sheldon L. Kaplan, MD<sup>9</sup>; <sup>1</sup>Baylor College of Medicine and Texas Children's Hospital, Houston, Texas; <sup>2</sup>Ohio State University College of Medicine and Public Health and Nationwide Children's Hospital, Columbus, Ohio; <sup>3</sup>University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania; <sup>4</sup>University of California San Diego, Dept of Pediatrics, School of Medicine, San Diego, California; <sup>5</sup>Wake Forest School of Medicine and Wake Forest Baptist Health, Winston Salem, North Carolina; <sup>6</sup>Feinberg School of Medicine, Northwestern University and Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois; <sup>7</sup>University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Arkansas; <sup>8</sup>Children's Hospital Los Angeles, Los Angeles, California; <sup>9</sup>Baylor College of Medicine, Houston, Texas

**Session:** 277. Vaccines: Bacterial  
 Saturday, October 5, 2019: 12:15 PM


**Background:** Pneumococcal acute otitis media (AOM) in children due to vaccine-related serotypes (ST) has declined after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13), although some serotypes, such as 3, 19A and 19F have persisted. Among non-vaccine serotypes, 35B has been shown to contribute substantially to both OM and invasive infections. This study describes the current epidemiology of pneumococcal OM isolates obtained from the U S Pediatric Multicenter Pneumococcal Surveillance Group (USPMPSG).

**Methods:** From the USPMPSG database, we collected data from patients <18 years of age with pneumococcal OM isolates from 2014 to 2018. Analysis included demographics, immunization status, antimicrobial susceptibility data and serotype. Statistical comparisons included Fisher's exact and Wilcoxon rank-sum tests.

**Results:** A total of 494 patients with isolates were identified within the time period from 5 children's hospitals. Median age was 1.7 years (range 0–17.6) and 299 (60.5%) were male; 176 (35.7%) had an underlying condition. Thirty-two patients had received no dose of either PCV7 or PCV13. Thirty-five serotypes were identified (3 isolates were non-typeable), of which 6 serotypes [35B (16.8%), 3 (9.5%), 15A (7.9%), 15B (7.9%), 23B (7.9%) and 21 (6.1%)] caused more than half of the total OM infections (figure). Ninety (18.2%) isolates were of PCV13 serotypes. Twenty-five of 476 (5.3%) isolates had a penicillin MIC>2 µg/mL. These were of serotypes 11A, 15A/C, 19A/F, 35B and NT; 10/455 (2.2%) isolates had ceftriaxone MIC>1 µg/mL and were of ST 3, 15A, 19A/F and 35B.

**Conclusion:** Most pneumococcal OM were caused by non-PCV13 serotypes. Serotype 35B remained the most common serotype among pneumococcal isolates recovered from ear drainage or middle ear cultures. The low proportion of penicillin-resistant isolates along with the increasing proportion of AOM cases being due to non-pneumococcal isolates supports the consideration to switch routine antibiotic treatment for AOM to standard dose amoxicillin-clavulanate from high dose amoxicillin in PCV13 immunized children (*Pediatr Infect Dis J* 2018;37:1255–1257).

Figure. Pneumococcal Serotypes Causing Otitis Media, 2014–2018



**Disclosures.** All authors: No reported disclosures.

**2708. Genetic Structure of Streptococcus pneumoniae Isolated from Invasive Disease in Korea, 2014–2016**

Ye Kyung Kim, MD<sup>1</sup>; Kyuyol Rhie, MD<sup>1</sup>; Yun Young Choi, MD<sup>1</sup>; Hoan J. Lee, MD, PhD<sup>2</sup>; Ki Wook Yun, MD, PhD<sup>3</sup>; Eun Hwa Choi, MD, PhD<sup>2</sup>; <sup>1</sup>Seoul National University Children's Hospital, Seoul, Seoul-t'ukpyolsi, Republic of Korea; <sup>2</sup>Seoul National University College of Medicine, Seoul, Seoul-t'ukpyolsi, Republic of Korea; <sup>3</sup>The Research Institute at Nationwide Children's Hospital, Columbus, Ohio

**Session:** 277. Vaccines: Bacterial  
 Saturday, October 5, 2019: 12:15 PM

**Background:** The extended-valency pneumococcal conjugate vaccines (PCVs) were implemented into Korean national immunization program in 2014. This study investigated the change in genetic structures of *Streptococcus pneumoniae* causing invasive pneumococcal disease (IPD) in Korean children after 10- and 13-valent conjugate vaccine (PCV10 and PCV13, respectively) use.

**Methods:** Between January 2014 and December 2016, invasive isolates were collected from 23 hospitals throughout Korea. Cases of IPD were defined by isolating pneumococci from normally sterile sites. Each pneumococcal isolate was identified using standard microbiological techniques and serotyped by Quellung reaction. The multi-locus sequence typing (MLST) was analyzed for randomly selected isolates.

**Results:** A total of 91 pneumococcal isolates were analyzed. Common serotypes were 10A (18.7%), 12F (11.0%), 15A (9.9%), 19A (9.9%), 15B/C (7.7%), 23A (6.6%), 35B (5.5%), and 23B (4.4%). The isolates belonged to 38 sequence types (STs), including 4 newly discovered STs. Of the 4 clonal complexes (CCs), 3 clonal complexes were antibiotic-resistant international clones. CC166 (11.9%) were associated with non-vaccine serotypes (NVTs); 11A, 15B/C, 23A, and 13). Serotypes of CC320 (10.9%) comprised of serotype 19A and 19F. The main serotypes responsible for CC81 (10.9%) were serogroup 15. New serotype-ST combinations were observed, especially in serotype 13 and serogroup 15. Also, a possibility of capsular switch event was noted between serogroup 6 and serogroup 15A).

**Conclusion:** The introduction of extended-valency PCVs has resulted in the change of the genetic structure of pneumococcal isolates in Korean children. This study demonstrates that selective pressure from PCV10/13 caused predominant serotypes to be NVTs and genetic changes such as capsular switch events.

**Disclosures.** All authors: No reported disclosures.

**2709. Immune Response After Diphtheria and Tetanus Toxoid in Patients with Adult-Onset Immunodeficiency with Anti-interferon-γ Autoantibody**

Dissaraj Tovikkai, MD<sup>1</sup>; Jakapat Vanichanan, MD<sup>2</sup>; Kamonwan Jutivorakool, MD<sup>2</sup>; <sup>1</sup>Chulalongkorn University, Vadhana, Krung Thep, Thailand; <sup>2</sup>King Chulalongkorn Memorial Hospital, Bangkok, Krung Thep, Thailand

**Session:** 277. Vaccines: Bacterial  
 Saturday, October 5, 2019: 12:15 PM

**Background:** Immunization were the key of prevention in tetanus and diphtheria disease. Nevertheless, in previous observational study, low seroprotection rate of both diphtheria and tetanus were observed in Thai healthy population. Reduced-dose diphtheria and tetanus toxoid vaccine (dT) was recommended to all adult patients regardless of immunologic status. However, data on vaccine efficacy in interferon gamma (IFN-γ) autoantibody were limited. We therefore conducted clinical study to evaluate efficacy and safety of one dose of dT in IFN-γ autoantibody patient compared with healthy individuals at 4 weeks after vaccination.

**Methods:** Study was conducted from February to April 2019. Total 18 patients with confirmed IFN-γ autoantibody were enrolled. Baseline tetanus and diphtheria serologic study and 4 weeks after vaccination were examined. Antibody levels were measured with a solid-phase IgG-specific ELISAs (EUROIMMUN, Germany). Geometric mean titers (GMTs) were calculated using the log transformation of serological titers and from taking the antilog mean of the transformed values.

**Results:** Seroprevalence of tetanus was 94.5% in healthy population compared with 60.1% in IFN-γ autoantibody patients. While, seroprevalence of diphtheria was 27.8% and 77.8%, respectively. After vaccination, all healthy adults had reached seroprotection level in both diphtheria and tetanus. For patients with IFN-γ autoantibody, 88.9% and 94.4% had anti-tetanus toxin IgG and anti-diphtheria toxin IgG level above 0.1 IU/mL, respectively. These results indicated seroconversion rate of 71% for tetanus and 75% for diphtheria after dT vaccination. (Table 2). In the subgroup analysis, unboosted IFN-γ autoantibody patient had lower tetanus seroconversion rate compared with previously boosted patient (50% vs 100%). Active infection was also associated with lower immune response after tetanus vaccination. There was no severe adverse event in both group.

**Conclusion:** This is the first study on immune response after dT vaccination in IFN-γ autoantibody patient. Seroconversion rate of dT vaccine in IFN-γ autoantibody patient were slightly lower than healthy adults. Active infection and previously unboosted patient provided lower immune response of tetanus.

Baseline characteristics	IFN-γ autoantibody (n=18)	Healthy adult (n=18)	p-value
Age	54.22 ± 14.03	44.11 ± 13.37	0.034*
Gender: Male	16 (88.9%)	8 (44.4%)	0.002*
Childhood vaccination	16 (88.9%)	17 (94.4%)	0.229
Residence			
Central	7 (38.9%)	14 (77.8%)	0.019*
Rural (border and adjacent province)	11 (61.1%)	2 (22.2%)	
History of tetanus booster	12 (66.7%)	11 (61.1%)	0.729
History of diphtheria booster	1 (5.6%)	5 (27.8%)	0.287
Comorbidity			
Diabetes mellitus	1 (5.6%)	2 (11.1%)	1
Hypertension	3 (16.7%)	1 (5.6%)	0.603
Dyslipidemia	3 (16.7%)	2 (11.1%)	1
Other autoimmune disease	3 (16.7%)	0 (0%)	0.229
Chronic kidney disease	5 (27.8%)	0 (0%)	0.049*
Cardiovascular disease	2 (11.1%)	0 (0%)	0.486
Proteinuria use	2 (11.1%)	0 (0%)	0.486
IbD	12 (66.7%)	3 (16.7%)	0.736
Hb	1150.11 ± 720.64	694.44 ± 150.48	
Absolute neutrophil count	7028.89 ± 6150.7	3780.28 ± 1016.14	0.011*
Absolute lymphocyte count	2127.22 ± 545.24	2504.44 ± 621.1	0.062
Absolute eosinophil count	800.44 ± 900.04	194.44 ± 171.10	0.015*

Table 1. Baseline characteristics between patients with IFN-γ autoantibody and healthy adults